(Q36790803)

16 August 2017

1 reference

title

Thirty years of cyclophosphamide: assessing the evidence (English)

1 reference

16 August 2017

F Houssiau

1

1 reference

PubMed ID

17432109

16 August 2017

language of work or name

1 reference

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

16

1 reference

16 August 2017

212-216

1 reference

16 August 2017

3

1 reference

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

16 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Comparison of quantitative and semiquantitative indicators of joint space narrowing in subjects with knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203306075613

21 January 2018

Identifiers

DOI

10.1177/0961203306075613

1 reference

16 August 2017

1 reference

PubMed ID

17432109